Who are overencapsulated caffeine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nourianz, Singulair, Neurontin, Lariam, Adenocard, Lariam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/overencapsulated-caffeine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

overencapsulated caffeine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

overencapsulated caffeine (overencapsulated caffeine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: stimulant. Area: Central Nervous System.

phase 3 stimulant adenosine receptor Central Nervous System Small molecule Live · refreshed every 30 min

Target snapshot

overencapsulated caffeine (overencapsulated caffeine) — Astellas Pharma Inc. Overencapsulated caffeine acts as a stimulant by increasing the levels of dopamine and norepinephrine in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
overencapsulated caffeine TARGET	overencapsulated caffeine	Astellas Pharma Inc	phase 3	stimulant	adenosine receptor
Nourianz	ISTRADEFYLLINE	Kyowa Kirin	marketed	CYP3A4 Substrates	Adenosine receptor A2a	2019-01-01
Singulair	montelukast	Merck & Co.	marketed	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
Neurontin	gabapentin	Generic (originally Parke-Davis/Pfizer)	marketed	Gabapentinoid (anticonvulsant/neuropathic pain agent)	Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor	1993-12-30
Lariam	MEFLOQUINE HYDROCHLORIDE		marketed	Antimalarial	Adenosine receptor A2a	1989-01-01
Adenocard	ADENOSINE	Astellas Pharma	marketed	Adenosine Receptor Agonist [EPC]	Adenosine receptor A3	1989-01-01
Lariam	MEFLOQUINE		marketed	Antimalarial	Adenosine receptor A2a	1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (stimulant class)

Astellas Pharma Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). overencapsulated caffeine — Competitive Intelligence Brief. https://druglandscape.com/ci/overencapsulated-caffeine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing